Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) Latest Company News

Sep 8, 2026, 13:54 UTC
On September 8, 2026, Wolwo Bio-Pharmaceutical announced that due to divorce property division, its actual controller changed from Hu Gengxi and Yanni Chen to Yanni Chen alone, with Hu Gengxi's direct shares and his stake in Mingchen Investment transferred to family members.
Source:
- wap.eastmoney.com
- stock.jrj.com.cn
Sep 8, 2026, 13:54 UTC
On September 8, 2026, Hu Gengxi resigned as chairman, director, and legal representative of Wolwo Bio-Pharmaceutical, effective immediately, and will no longer hold any position in the company.
Source:
Sep 8, 2026, 11:05 UTC
On September 8, 2026, Hu Gengxi and YANNI CHEN dissolved their marriage and split property, resulting in Hu Gengxi holding 8.35% of Myhealth Biotechnology, becoming a single shareholder above 5%.
Source:
- finance.sina.cn
- m.21jingji.com
Sep 8, 2026, 11:05 UTC
Hu Gengxi resigned as chairman, director, and legal representative of Myhealth Biotechnology on September 8, 2026.
Source:
- finance.sina.cn
- finance.sina.cn
Aug 27, 2026, 10:29 UTC
Wolwo Bio-Pharmaceutical announced its 2026 first-half results: net profit attributable to shareholders of 213 million yuan, up 20.59% year-on-year.
Source:
- finance.sina.cn
Aug 21, 2026, 09:10 UTC
China's National Medical Products Administration approved Wolwo Bio-Pharmaceutical's clinical trial application for its cat dander membrane agent, a Class 1 therapeutic biological product, for allergic rhinitis related to cat dander sensitization.
Source:
- finance.sina.cn

300357.SZ

On September 8, 2026, Wolwo Bio-Pharmaceutical announced that due to divorce property division, its actual controller changed from Hu Gengxi and Yanni Chen to Yanni Chen alone, with Hu Gengxi's direct shares and his stake in Mingchen Investment transferred to family members.

On September 8, 2026, Hu Gengxi resigned as chairman, director, and legal representative of Wolwo Bio-Pharmaceutical, effective immediately, and will no longer hold any position in the company.

On September 8, 2026, Hu Gengxi and YANNI CHEN dissolved their marriage and split property, resulting in Hu Gengxi holding 8.35% of Myhealth Biotechnology, becoming a single shareholder above 5%.

Hu Gengxi resigned as chairman, director, and legal representative of Myhealth Biotechnology on September 8, 2026.

Wolwo Bio-Pharmaceutical announced its 2026 first-half results: net profit attributable to shareholders of 213 million yuan, up 20.59% year-on-year.

China's National Medical Products Administration approved Wolwo Bio-Pharmaceutical's clinical trial application for its cat dander membrane agent, a Class 1 therapeutic biological product, for allergic rhinitis related to cat dander sensitization.